Thomas S. Lytle
Profile
Thomas S.
Lytle joined Cytogen in April 2004 as our Senior Vice President, Sales and Marketing.
Prior to joining Cytogen, He was with Amgen, Inc. from 1997 to January 2004 where he held senior marketing positions, including Vice President of Strategic Marketing and Business Development, and Vice President of New Products Marketing.
He began his career in the health care industry when he joined Pfizer, Inc. in 1971 and, during more than 20 years with Pfizer, he gained a broad range of industry experience in a series of sales, marketing and marketing management positions in several therapeutic categories.
Further, as Vice President of Marketing for Lederle Laboratories, a division of American Cyanamid, from 1989 to 1991, he had responsibility for a broad range of anti-infective, oncology, cardiovascular, and anti-inflammatory products.
He holds an MBA in Marketing from LaSalle University, and a BBA in Marketing from Western Michigan University.
In 1993, he retired from the United States Army Reserve as a Colonel.
Former positions of Thomas S. Lytle
Companies | Position | End |
---|---|---|
Jazz Pharmaceuticals (EUSA Pharma USA), Inc.
Jazz Pharmaceuticals (EUSA Pharma USA), Inc. BiotechnologyHealth Technology Jazz Pharmaceuticals (EUSA Pharma USA), Inc. develops and markets biopharmaceutical products. The company was founded on November 7, 1980 and is headquartered in Princeton, NJ. | Sales & Marketing | 30/10/2005 |
Neogenix Oncology, Inc.
Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer. | Chief Operating Officer | - |
Training of Thomas S. Lytle
LaSalle University | Masters Business Admin |
Western Michigan University | Undergraduate Degree |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Jazz Pharmaceuticals (EUSA Pharma USA), Inc.
Jazz Pharmaceuticals (EUSA Pharma USA), Inc. BiotechnologyHealth Technology Jazz Pharmaceuticals (EUSA Pharma USA), Inc. develops and markets biopharmaceutical products. The company was founded on November 7, 1980 and is headquartered in Princeton, NJ. | Health Technology |
Neogenix Oncology, Inc.
Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer. | Health Technology |
- Stock Market
- Insiders
- Thomas S. Lytle